Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Lyell Immunopharma (Nasdaq: LYEL) said senior management will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026 at 11:00 AM ET. A live webcast will be available via the company investor website, with a replay posted after the presentation.
The presentation covers Lyell's late-stage CAR T-cell therapy pipeline and provides an opportunity for investor questions and management commentary.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – LYEL
On the day this news was published, LYEL gained 0.41%, reflecting a mild positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $530.70M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows ACIU up 6.30% and IVVD up 4.62%. LYEL’s own intraday direction was not specified, so sector alignment cannot be fully assessed.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Earnings and updates | Neutral | -14.2% | Reported 2025 net loss and cash position alongside clinical and business updates. |
| Mar 09 | Private placement, CFO | Positive | +13.5% | Closed additional $50M equity tranche and appointed new Chief Financial and Business Officer. |
| Feb 23 | Investor conferences | Neutral | +6.1% | Announced management participation in multiple early-March investor conferences. |
| Feb 12 | Phase 3 trial start | Positive | +4.3% | Initiated patient dosing in Phase 3 PiNACLE-H2H head-to-head CAR T trial. |
| Dec 07 | Clinical data update | Positive | +12.3% | Presented strong ronde-cel LBCL data with high ORR and CR rates at ASH. |
Recent clinical and financing updates have triggered sizable price swings, while conference-related news has also coincided with meaningful moves.
Over the last few months, LYEL has reported major clinical, financial, and strategic milestones. On Dec 7, 2025, strong ronde-cel data with high response rates preceded a 12.32% gain. Initiation of the Phase 3 PiNACLE-H2H trial on Feb 12, 2026 was followed by a 4.27% move. A March private placement and CFO appointment on Mar 9, 2026 coincided with a 13.54% rise, while Q4 and full-year 2025 results on Mar 12, 2026 saw a -14.23% reaction. A March conference participation update linked with a 6.12% move, framing today’s Needham conference news within a pattern of event-driven volatility.
Regulatory & Risk Context
An active S-3 shelf registration dated Apr 3, 2026 covers the resale of 1,952,360 shares of common stock issued at a Milestone Closing. The filing states it is solely for selling stockholders’ resale and that Lyell will not receive proceeds from these sales, though it has paid registration expenses.
Market Pulse Summary
This announcement highlights LYEL’s participation in the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, offering investors another forum to hear from senior management. It follows recent earnings, clinical, and financing disclosures, as well as an S-3 registration for resale of existing shares. Investors may watch the webcast for any updates on the CAR T-cell pipeline, capital position, and timelines relative to the milestones described in recent SEC filings.
Key Terms
car t-cell therapies medical
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 11:00 am Eastern Time.
A live webcast of the presentation can be accessed through the Investors section of the Company's website at www.lyell.com. A replay of the webcast will be available on the Company's website following the presentation date.
About Lyell
Lyell is a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to arm CAR T cells with enhancements needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. Lyell’s LyFE Manufacturing Center™ has commercial launch capability and can manufacture more than 1,200 CAR T-cell doses at full capacity. To learn more, please visit www.lyell.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: Lyell management’s planned presentation and participation at an investor conference; the potential clinical benefits and therapeutic potential of Lyell’s product candidates; and the sufficiency of the capacity of LyFE to manufacture drug supply through potential commercial launch. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties described under the heading “Risk Factors” in Lyell’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.
Contact:
Pablo Fenton
Associate Director, Investor Relations and Corporate Communications
pfenton@lyell.com
